atypicalfractures database

This is a database for a case-control study nested in the Spanish database BIFAP (Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria, Database for Pharmacoepidemiologic Research in Primary Care). This is a longitudinal population-based database maintained by the Spanish Agency for Medicines and Medical Devices that collects, from 2001 onwards, the computerized medical records of >3.2 million patients attended by more than 1,800 primary care physicians throughout Spain. It includes anonymized information on >13.7 million person-years of follow up

Relationship between the degree of proliferation of non-lymphoid CD34⁺ and nucleated red blood cells from patients with myelodysplastic syndromes (MDS) and other haematological and biochemical characteristics of the disease.

<p>Results expressed as number of cases from all MDS patients analyzed and percentage between brackets.</p><p>PI, proliferation index;</p><p>LDH, lactate dehydrogenase;</p><p>AL, acute leukemia;</p><p>NS, statistically not significantly different.</p

Proliferation index (percentage of S+G₂M cells) of different compartments of bone marrow (BM) cells in MDS patients grouped according to the World Health Organization (WHO) classification and the International Prognostic Scoring System (IPSS).

<p>Results expressed as median percentage of S+G₂ M cells and range between brackets. RA, refractory anemia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, RA with excess of blasts; MD/MPN, myelodysplastic/myeloproliferative neoplasms; INT, intermediate risk; NS, statistically not significantly different.</p>†<p>, p<0.05 and</p>††<p>, p<0.03 <i>vs.</i> normal/reactive BM.</p

Proliferation index (percentage of S+G₂M cells) of different BM cell compartments in MDS <i>vs</i>. both AML and normal/reactive BM.

<p>Results expressed as median percentage of S+G₂/M cells and range between brackets. AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; BM, bone marrow; NS, statistically not significantly different;</p>†<p>, MDS <i>vs</i>. normal/reactive BM;</p>¥<p>, MDS <i>vs</i>. AML;</p>*<p>, AML <i>vs.</i> normal/reactive BM.</p

Proliferation index (percentage of S+G₂M cells) of different BM cell compartments in normal/reactive BM (n = 94) and MDS patients (n = 106) with normal/favourable (n = 83) versus intermediate/poor (n = 23) cytogenetics.

<p>Results expressed as median percentage of cells and range between brackets.</p>*<p>, p<0.05 and</p>**<p>, p<0.03 <i>vs.</i> normal/reactive BM; and;</p>‡‡<p><b>,</b> p<0.03 <i>vs.</i> normal/favourable karyotype. Normal/favourable cytogenetics includes cases with a normal karyotype, -Y, del(5q) or isolated del(7q); poor cytogenetics includes cases with complex (≥3 chromosomal abnormalities) karyotypes and alterations of chromosome 7, except isolated del(7q), and; intermediate cytogenetics: other karyotypic abnormalities.</p

Impact of currently used prognostic classifications and other disease features on overall survival and risk of transformation to acute leukemia (AL) of patients with myelodysplastic syndromes (MDS; n = 106).

<p>Overall survival (left column) and progression-free survival (transformation to AL; right column) curves are plotted for patients with MDS grouped according to the International Prognostic Scoring System (IPSS; row A), the World Health Organization-based Scoring System (WPSS; row B), the number of peripheral blood platelets at diagnosis (row C), the presence of multiple cytopenias (row D), transfusion dependency (row E), and serum LDH levels (row F).</p

Impact of the proliferation index (PI) of BM non-lymphoid (e.g.: myeloid plus immature) CD34⁺ precursors and nucleated red blood cells (NRBC) on the overall survival and progression (transformation to acute leukemia; AL) free survival of patients with myelodysplastic syndromes (MDS).

<p>Overall survival and progression-free survival curves are plotted for groups of MDS patients classified according to the PI of non-lymphoid (e.g.: myeloid plus immature) CD34⁺ cells (panels A to D) and NRBC (panels E to H). In the left column all MDS patients (n = 106) are analyzed together, while in the right column only MDS patients in the low plus intermediate-1 IPSS risk categories (n = 56) are considered.</p

Prognostic factors for overall survival (OS) and progression (transformation to acute leukemia)-free survival (PFS) in MDS.

<p>PI, proliferation index; NRBC, nucleated red blood cells; LDH, lactate dehydrogenase; AL, acute leukemia;</p>*<p>OS, overall survival expressed in months; PFS: progression to acute leukemia-free survival expressed in months; HR, hazard ratio.</p